---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-037296"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:51:56.021922+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TELA Bio reports record 2023 revenue $58.5M (+41% YoY); guides FY2024 $74-76M

## Summary
- Q4 revenue $17.0M (+46% YoY); full-year revenue $58.5M (+41% YoY).
- Net loss $12.9M in Q4, $46.7M for FY 2023; cash $46.7M at year-end.
- FY 2024 revenue guidance $74-76M (27-30% YoY growth).
- Launched LIQUIFIX FIX8 and Precision, FDA-approved liquid adhesive for hernia mesh fixation.
- Sold NIVIS distribution rights to MiMedx for $8-12M cash consideration.

## SEC filing metadata
- accession: 0001104659-24-037296
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465924037296/0001104659-24-037296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465924037296/tm249241d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-037296
- JSON: https://secwatch.observer/filing/0001104659-24-037296.json
- Plain text: https://secwatch.observer/filing/0001104659-24-037296.txt

## Key facts
- Earnings Releases
  TELA Bio, Inc. reported the fourth quarter of 2023 results: revenue $17.0 million, net income $12.9 million. Guidance initiated.
  - Period: the fourth quarter of 2023
  - Revenue: $17.0 million
  - Net income: $12.9 million
  - Guidance: initiated
  - Result: reported results
  source text: Revenue was $17.0 million in the fourth quarter of 2023, an increase of 46% compared to the same period in 2022. The increase was due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales. Gross profit was $11.6 million in the fourth quarter of 2023, or 68% of revenue, compared to $8.2 million, or 70% of revenue, in the same period in 2022. The slight decrease in gross margin was primarily due to an increase in our excess and obsolete inventory adjustments. Operating expenses were $23.9 million in the fourth quarter of 2023, compared to $17.6 million in the same period in 2022. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, consulting and professional fees. Loss from operatio
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465924037296/0001104659-24-037296-index.htm
- Earnings Releases
  TELA Bio, Inc. reported the fiscal year ended December 31, 2023 results: revenue $58.5 million, net income $46.7 million. Guidance initiated.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $58.5 million
  - Net income: $46.7 million
  - Guidance: initiated
  - Result: reported results
  source text: Revenue was $58.5 million for the full year 2023, an increase of 41% compared to the same period in 2022. The increase was primarily due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales. Gross profit was $40.1 million in the full year 2023, or 69% of revenue, compared to $27.0 million, or 65% of revenue, in 2022. The increase in gross margin was primarily due to improved inventory management processes and lower amortization of intangible assets. Operating expenses were $84.2 million in the full year of 2023, compared to $66.1 million in 2022. The increase was due to higher compensation costs and employee-related expenses from additional headcount as we continue to expand our organization, as well as increased travel, consulting and professional fees. Loss from operations was $44.1 million in the ful
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465924037296/0001104659-24-037296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.